What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Fabio Turco¹, Andrew Armstrong², Gerhardt Attard³, Tomasz M Beer⁴, Himisha Beltran⁵, Anders Bjartell⁶, Alberto Bossi⁷, Alberto Briganti⁸, Rob G Bristow⁹, Muhammad Bulbul¹⁰, Orazio Caffo¹¹, Kim N Chi¹², Caroline Clarke¹³, Noel Clarke¹⁴, Ian D Davis¹⁵, Johann de Bono¹⁶, Ignacio Duran¹⁷, Ros Eeles¹⁸, Eleni Efstathiou¹⁹, Jason Efstathiou²⁰, Christopher P Evans²¹, Stefano Fanti²², Felix Y Feng²³, Karim Fizazi²⁴, Mark Frydenberg²⁵, Dan George²⁶, Martin Gleave²⁷, Susan Halabi²⁸, Daniel Heinrich²⁹, Celestia Higano³⁰, Michael S Hofman³¹, Maha Hussain³², Nicholas James³³, Rob Jones³⁴, Ravindran Kanesvaran³⁵, Raja B Khauli³⁶, Laurence Klotz³⁷, Raya Leibowitz³⁸, Christopher Logothetis³⁹, Fernando Maluf⁴⁰, Robin Millman⁴¹, Alicia K Morgans⁵, Michael J Morris⁴², Nicolas Mottet⁴³, Hind Mrabti⁴⁴, Declan G Murphy⁴⁵, Vedang Murthy⁴⁶, William K Oh⁴⁷, Ngozi Ekeke Onyeanunam⁴⁸, Piet Ost⁴⁹, Joe M O'Sullivan⁵⁰, Anwar R Padhani⁵¹, Christopher Parker⁵², Darren M C Poon⁵³, Colin C Pritchard⁵⁴, Danny M Rabah⁵⁵, Dana Rathkopf⁵⁶, Robert E Reiter⁵⁷, Mark Rubin⁵⁸, Charles J Ryan⁵⁹, Fred Saad⁶⁰, Juan Pablo Sade⁶¹, Oliver Sartor⁶², Howard I Scher⁶³, Neal Shore⁶⁴, Iwona Skoneczna⁶⁵, Eric Small⁶⁶, Matthew Smith⁶⁷, Howard Soule⁶⁸, Daniel Spratt⁶⁹, Cora N Sternberg⁷⁰, Hiroyoshi Suzuki⁷¹, Christopher Sweeney⁷², Matthew Sydes⁷³, Mary-Ellen Taplin⁷², Derya Tilki⁷⁴, Bertrand Tombal⁷⁵, Levent Türkeri⁷⁶, Hiroji Uemura⁷⁷, Hirotsugu Uemura⁷⁸, Inge van Oort⁷⁹, Kosj Yamoah⁸⁰, Dingwei Ye⁸¹, Almudena Zapatero⁸², Silke Gillessen⁸³, Aurelius Omlin⁸⁴

Affiliations

¹ Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. Electronic address: turcofabio9@gmail.com.
² Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
³ University College London Cancer Institute, London, UK.
⁴ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
⁵ Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁶ Department of Urology, Skåne University Hospital, Malmö, Sweden.
⁷ Genito Urinary Oncology, Prostate Brachytherapy Unit, Goustave Roussy, Paris, France.
⁸ Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
⁹ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK.
¹⁰ Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
¹¹ Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
¹² BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
¹³ Research Department of Primary Care & Population Health, Royal Free Campus, University College London, Rowland Hill St, London, UK.
¹⁴ The Christie and Salford Royal Hospitals, Manchester, UK.
¹⁵ Monash University and Eastern Health, Victoria, Australia.
¹⁶ The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Surrey, UK.
¹⁷ Department of Medical Oncology. Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
¹⁸ The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
¹⁹ Houston Methodist Cancer Center, Houston, TX, USA.
²⁰ Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
²¹ University of California Davis School of Medicine, Sacramento, CA, USA.
²² Policlinico S. Orsola, Università di Bologna, Bologna, Italy.
²³ University of California, San Francisco, San Francisco, CA, USA.
²⁴ Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
²⁵ Department of Surgery, Monash University, Melbourne, Australia; Prostate Cancer Research Program, Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia.
²⁶ Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
²⁷ Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
²⁸ Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
²⁹ Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
³⁰ University of British Columbia, Vancouver, British Columbia, Canada.
³¹ Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
³² Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
³³ The Institute of Cancer Research, London, UK.
³⁴ Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
³⁵ Division of Medical Oncology, National Cancer Centre, Singapore.
³⁶ Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon.
³⁷ Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
³⁸ Oncology institute, Shamir Medical Center, Zerifin, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
³⁹ Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA; Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; David H. Koch Centre, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Centre, Houston, TX, USA.
⁴⁰ Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brazil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
⁴¹ Patient Advocate, UK.
⁴² Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴³ University Hospital Nord St Etienne, St Etienne, France.
⁴⁴ National Institute of Oncology, University hospital, Rabat, Morocco.
⁴⁵ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
⁴⁶ Tata Memorial Centre, Mumbai, India.
⁴⁷ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
⁴⁸ Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria.
⁴⁹ Department of Radiation Oncology, Iridium Netwerk, Wilrijk (Antwerp), Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
⁵⁰ Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland; Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland.
⁵¹ Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK.
⁵² Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
⁵³ Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, The Chinese University of Hong Kong, Hong Kong.
⁵⁴ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
⁵⁵ The Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
⁵⁶ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵⁷ University of California Los Angeles, Los Angeles, CA, USA.
⁵⁸ Bern Center for Precision Medicine, Bern, Switzerland; Department for Biomedical Research, University of Bern, Bern, Switzerland.
⁵⁹ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
⁶⁰ Centre Hospitalier de Université de Montréal, Montreal, Canada.
⁶¹ Instituto Alexander Fleming, Buenos Aires, Argentina.
⁶² Tulane Cancer Center, New Orleans, LA, USA.
⁶³ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
⁶⁴ Carolina Urologic Research Center, Myrtle Beach, SC, USA.
⁶⁵ Rafal Masztak Grochowski Hospital in Warsaw, Warsaw, Poland; Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
⁶⁶ UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
⁶⁷ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
⁶⁸ Prostate Cancer Foundation, Santa Monica, CA, USA.
⁶⁹ University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁷⁰ Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
⁷¹ Toho University Sakura Medical Center, Chiba, Japan.
⁷² Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷³ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
⁷⁴ Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
⁷⁵ Cliniques Universitaires Saint Luc, Brussels, Belgium.
⁷⁶ Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
⁷⁷ Yokohama City University Medical Center, Yokohama, Japan.
⁷⁸ Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
⁷⁹ Radboud University Medical Center, Nijmegen, The Netherlands.
⁸⁰ Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA.
⁸¹ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
⁸² Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain.
⁸³ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Universita della Svizzera Italiana, Lugano, Switzerland; Cantonal Hospital, St. Gallen, Switzerland; University of Bern, Bern, Switzerland; Division of Cancer Science, University of Manchester, Manchester, UK.
⁸⁴ University of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland.

PMID: 35393158
PMCID: PMC8849852
DOI: 10.1016/j.eururo.2022.02.010

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Fabio Turco et al. Eur Urol. 2022 Jul.

. 2022 Jul;82(1):6-11.

doi: 10.1016/j.eururo.2022.02.010. Epub 2022 Feb 17.

Authors

Affiliations

¹ Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. Electronic address: turcofabio9@gmail.com.
² Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
³ University College London Cancer Institute, London, UK.
⁴ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
⁵ Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁶ Department of Urology, Skåne University Hospital, Malmö, Sweden.
⁷ Genito Urinary Oncology, Prostate Brachytherapy Unit, Goustave Roussy, Paris, France.
⁸ Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
⁹ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK.
¹⁰ Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
¹¹ Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
¹² BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
¹³ Research Department of Primary Care & Population Health, Royal Free Campus, University College London, Rowland Hill St, London, UK.
¹⁴ The Christie and Salford Royal Hospitals, Manchester, UK.
¹⁵ Monash University and Eastern Health, Victoria, Australia.
¹⁶ The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Surrey, UK.
¹⁷ Department of Medical Oncology. Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
¹⁸ The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
¹⁹ Houston Methodist Cancer Center, Houston, TX, USA.
²⁰ Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
²¹ University of California Davis School of Medicine, Sacramento, CA, USA.
²² Policlinico S. Orsola, Università di Bologna, Bologna, Italy.
²³ University of California, San Francisco, San Francisco, CA, USA.
²⁴ Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
²⁵ Department of Surgery, Monash University, Melbourne, Australia; Prostate Cancer Research Program, Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia.
²⁶ Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
²⁷ Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
²⁸ Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
²⁹ Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
³⁰ University of British Columbia, Vancouver, British Columbia, Canada.
³¹ Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
³² Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
³³ The Institute of Cancer Research, London, UK.
³⁴ Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
³⁵ Division of Medical Oncology, National Cancer Centre, Singapore.
³⁶ Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon.
³⁷ Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
³⁸ Oncology institute, Shamir Medical Center, Zerifin, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
³⁹ Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA; Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; David H. Koch Centre, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Centre, Houston, TX, USA.
⁴⁰ Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brazil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
⁴¹ Patient Advocate, UK.
⁴² Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴³ University Hospital Nord St Etienne, St Etienne, France.
⁴⁴ National Institute of Oncology, University hospital, Rabat, Morocco.
⁴⁵ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
⁴⁶ Tata Memorial Centre, Mumbai, India.
⁴⁷ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
⁴⁸ Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria.
⁴⁹ Department of Radiation Oncology, Iridium Netwerk, Wilrijk (Antwerp), Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
⁵⁰ Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland; Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland.
⁵¹ Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK.
⁵² Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
⁵³ Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, The Chinese University of Hong Kong, Hong Kong.
⁵⁴ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
⁵⁵ The Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
⁵⁶ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵⁷ University of California Los Angeles, Los Angeles, CA, USA.
⁵⁸ Bern Center for Precision Medicine, Bern, Switzerland; Department for Biomedical Research, University of Bern, Bern, Switzerland.
⁵⁹ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
⁶⁰ Centre Hospitalier de Université de Montréal, Montreal, Canada.
⁶¹ Instituto Alexander Fleming, Buenos Aires, Argentina.
⁶² Tulane Cancer Center, New Orleans, LA, USA.
⁶³ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
⁶⁴ Carolina Urologic Research Center, Myrtle Beach, SC, USA.
⁶⁵ Rafal Masztak Grochowski Hospital in Warsaw, Warsaw, Poland; Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
⁶⁶ UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
⁶⁷ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
⁶⁸ Prostate Cancer Foundation, Santa Monica, CA, USA.
⁶⁹ University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁷⁰ Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
⁷¹ Toho University Sakura Medical Center, Chiba, Japan.
⁷² Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷³ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
⁷⁴ Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
⁷⁵ Cliniques Universitaires Saint Luc, Brussels, Belgium.
⁷⁶ Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
⁷⁷ Yokohama City University Medical Center, Yokohama, Japan.
⁷⁸ Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
⁷⁹ Radboud University Medical Center, Nijmegen, The Netherlands.
⁸⁰ Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA.
⁸¹ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
⁸² Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain.
⁸³ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Universita della Svizzera Italiana, Lugano, Switzerland; Cantonal Hospital, St. Gallen, Switzerland; University of Bern, Bern, Switzerland; Division of Cancer Science, University of Manchester, Manchester, UK.
⁸⁴ University of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland.

PMID: 35393158
PMCID: PMC8849852
DOI: 10.1016/j.eururo.2022.02.010

Erratum in

Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Turco F, et al. Eur Urol. 2022 Jul;82(1):e18-e19. doi: 10.1016/j.eururo.2022.04.004. Epub 2022 Apr 16. Eur Urol. 2022. PMID: 35440417 Free PMC article. No abstract available.

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

Keywords: COVID-19 boost injection; COVID-19 pandemic; COVID-19 vaccine; Prostate cancer; Prostate cancer management; Telemedicine.

PubMed Disclaimer

Comment in

Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6-11.
Wei Y, Zhu Y, Ye D. Wei Y, et al. Eur Urol. 2022 Jul;82(1):e14. doi: 10.1016/j.eururo.2022.03.030. Epub 2022 Mar 28. Eur Urol. 2022. PMID: 35393161 Free PMC article. No abstract available.
Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6-11.
Turco F, Smith M, Omlin A, Gillessen S. Turco F, et al. Eur Urol. 2022 Jul;82(1):e13. doi: 10.1016/j.eururo.2022.03.029. Epub 2022 Mar 28. Eur Urol. 2022. PMID: 35469701 Free PMC article. No abstract available.

References

1. Gillessen S., Powles T. Advice regarding systemic therapy in patients with urological cancers during the COVID-19 pandemic. Eur Urol. 2020;77:667–668. - PMC - PubMed
1. Caffo O., Messina M., Veccia A., Kinspergher S., Maines F., Messina C. Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review. Crit Rev Oncol Hematol. 2021;167:103491. - PMC - PubMed
1. Nguyen P.L., Alibhai S.M., Basaria S., et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–836. - PubMed
1. Montopoli M., Zumerle S., Vettor R., et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) Ann Oncol. 2020;31:1040–1045. - PMC - PubMed
1. Sari Motlagh R., Abufaraj M., Karakiewicz P.I., et al. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. World J Urol. 2022 doi: 10.1007/s00345-021-03810-6. In press. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Affiliations

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Authors

Affiliations

Erratum in

Abstract

Comment in

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical